Growth hormone deficiency (GHD) results from inadequate secretion of growth hormone, characterized prominently by short stature. Acromegaly (ACRO) occurs due to the overproduction of growth hormone in the body, resulting in symptoms and physical traits manifested by enlarged extremities.

?

Persistent and untreated GHD and ACRO can lead to metabolic disturbances, cardiovascular diseases, and other symptoms that significantly impact patients' quality of life and lifespan. It is therefore imperative to identify and treat GHD and ACRO during their early stages. Human growth hormone (hGH) and insulin-like growth factor-1 (IGF-1) are crucial serum markers used for diagnosing and monitoring the treatment of GHD and ACRO. ^[1][2]

Clinical Applications of hGH and IGF-1

The GH-IGFs axis stimulates the liver to produce IGF-1 in response to hGH, thereby regulating growth, development, and metabolic processes.

Due to advances in hGH and IGF-1 detection technologies, testing for these hormones has become crucial for diagnosing and monitoring disorders associated with growth hormone secretion.

?

Meanwhile, scientists have discovered that the challenges in detecting hGH and IGF-1 in clinical settings include the selection of reference standards, interference from analogues, and accurate interpretation of clinical results. ^[3]

In response to these challenges, Mindray has developed the hGH and IGF-1 Chemiluminescence Assay Kits, a result of years of innovation. With standardized traceability, well-defined performance validation, and thorough clinical application assessment, these kits excel in resisting interference and providing precise clinical diagnoses.

Accurate detection of hGH and IGF-1 levels is essential for diagnosing and monitoring diseases related to the GH-IGFs axis. Mindray is dedicated to meeting clinical needs by seamlessly integrating every facet of our value chain, from raw material design to reagent production. This approach allows us to develop diagnostic assays ideally suited for clinical settings.

?

We will continue to improve our growth hormone assays by working closely with clinical professionals, innovating even more quality products that redefine medical diagnostics.

References:

[1] The Subspecialty Group of Endocrinology, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association. "Chinese guidelines for the diagnosis and treatment of pediatric growth hormone deficiency." Chinese Journal of Pediatrics 62.01 (2024): 5-11.

[2] Duan Lian et al. "Updated key points of Chinese Consensus for the Diagnosis and Treatment of Acromegaly (2021 edition)." Chinese Medical Journal 101.27 (2021): 4.

[3] Junnila, Riia K., Christian J. Strasburger, and Martin Bidlingmaier. "Pitfalls of insulin-like growth factor-I and growth hormone assays." Endocrinology and Metabolism Clinics 44.1 (2015): 27-34.

[4] The Subspecialty Group of Endocrinology, Hereditary and Metabolic Diseases, the Society of Pediatrics, Chinese Medical Association et al. "Chinese expert consensus on the diagnosis and treatment of children with idiopathic short stature." Chinese Journal of Practical Pediatrics 38.11(2023):801-813.